Home | Europe

CureVac fails in COVID-19 vaccine trial with 47% efficacy

By Ouyang Xueyan | chinadaily.com.cn | Updated: 2021-06-18 00:04

German biotech CureVac's COVID-19 vaccine has come out of a late-stage trial with 47 percent efficacy but the health ministry has said this will not impact the country's vaccination rollout.

Photo

Beijing-Tianjin-Hebei 2025 celebrations shine at Zhengding county

Revelers defy rain to welcome the New Year in Times Square

A summer of golden memories

China's unfolding story of innovation, unity and influence

Efforts in opening-up, innovation to inject impetus into business

Highlights of President Xi's 2025 New Year address

Robots no more science fiction in real life

East to west industry shift boon for nation

Trump's game, China's move

Editor's Pick

World's longest expressway tunnel built in Xinjiang

Borderland eco-governance beneficial beyond China

25th anniversary of Macao SAR

Xi attends APEC and G20

2024 Vision China

2024 FOCAC Summit

Global Edition

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.

BACK TO THE TOP

China Edition

中文

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.

License for publishing multimedia online 0108263

Registration Number: 130349

About China Daily

Advertise on Site

Expat Employment